HIF-1 resolves a ®rst mystery of VHL
In comparison with oncogenes which reveal their functions relatively easily, tumor suppressors are habitually more puzzling. In von Hippel-Linday (VHL) syndrome, a familiar cancer caused by germline mutations of the VHL tumor suppressor gene (Latif et al., 1993) , inactivation of the pVHL protein was found in renal carcinomas and hemangioblastomas, highly vascular tumors which overproduce angiogenic peptides including VEGF (Ohh and Kaelin, 1999) . In response to hypoxia, cells secrete VEGF that stimulate endothelial cell proliferation and formation of novel vessels, and angiogenesis is absolutely required for tumor growth. VHL-associated tumor cells express high levels of mRNA of all hypoxia-inducible genes in both normoxic (normal oxygen levels) and hypoxic conditions (Iliopoulos et al., 1996) , yet VHL is not a transcription regulator. Meantime, hypoxia-inducible transcription factor 1 (HIF-1) has been identi®ed that mediates expression of erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporters, glycolytic enzymes and other hypoxia-inducible genes (Semenza and Wang, 1992; Semenza, 2000; Guillemin and Krasnow, 1997) .
If VHL is linked to HIF-1, this explains why all HIF-1-dependent genes are upregulated when VHL is mutated or lost. Two features suggested a plausible connection. First, HIF-1 activity is regulated by HIF-1 protein degradation (Huang et al., 1996 (Huang et al., , 1998 . In normal conditions, the HIF-1 protein is rapidly degraded by the proteasome, whereas in hypoxia this degradation is ceased and HIF-1 accumulates and transactivates the target genes. Second, VHL forms complexes with other proteins including elongins that expected to possess ubiquitin ligase activity targeting speci®c proteins for degradation by the proteasome (Pause et al., 1999) .
Materializing this link, it has been demonstrated that VHL binds to HIF-1a and targets it for degradation under normal oxygen conditions (Maxwell et al., 1999) . pVHL, through its b-domain, binds directly to HIF, thereby targeting HIF for ubiquitination in an a-domain-dependent manner (Ohh et al., 2000) . Under hypoxia, HIF-1a is dissociated from pVHL thus preventing its degradation. When VHL is lost or mutated, HIF-1a is not degraded and is accumulated in normoxic conditions. Therefore, constitutive HIF-1 activation may underlie the angiogenic phenotype of tumors with VHL abnormalities.
In light of this elegant model, the analysis of interactions between p53 and Mdm-2 (tumor suppressor and its antagonist, respectively) suggests that the ®nal link between pVHL and HIF-1 might be missing. As I will discuss, however, the resemblance of p53 and HIF is concealed because: (i) the roles of tumor suppressors and their oncogenic antagonists are reversed in these systems, and (ii) the links between proteins were found in the opposite historical order.
The tumor suppressor p53 and Mdm-2
The tumor suppressor p53 is a transcriptional factor and mdm-2 is one of the ®rst identi®ed transcriptional targets of p53 (see for reference Ko and Prives, 1996; Lane and Hall, 1997) . This ®rst simple link that wildtype (wt) p53 induces Mdm-2, spotlights neither p53 nor Mdm-2 functions. While wt p53 is a tumor suppressor, Mdm-2 is an oncogene overexpressed in some cancers (Oliner et al., 1992) . Mutations of p53 leading to the loss of its transcriptional function are the most common genetic alterations in human cancers. One of the features of a mutant p53 is an unusually high protein stability. While wt p53 is rapidly degraded, mutant p53 is overexpressed in a cell. This puzzle was resolved by establishing a second link between p53 and Mdm-2. Although in a dierent historical order, the following paradigms were helpful to establish the second link between p53 and Mdm-2: (i) Wt p53 is rapidly degraded by the proteasome and therefore is expressed at low cellular levels; (ii) following DNA damage, wt p53 degradation is stopped and p53 accumulates and transactivates target genes; (iii) mutant p53 which loses its transactivation function accumulates at high levels. Theoretical analysis of these situations have led to the conclusion that some p53-inducible proteins must target wt p53 for degradation (Blagosklonny, 1997) . In fact, Mdm-2 is a protein that targets p53 for degradation (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997) . Mutant p53 does not transactivate mdm-2 and levels of Mdm-2 are too low to degrade mutant p53, causing mutant p53 accumulation. Following DNA damage, modi®cations of Mdm-2 and wt p53 results in loss of their interactions and wt p53 accumulation (Giaccia and Kastan, 1998) . Thus, the regulation of HIF-1a by VHL is almost identical to the regulation of p53 by Mdm-2 ( Figure  1 ).
Missing link between VHL and HIF
The striking similarity between functioning of HIFa/ VHL and p53/mdm-2 pairs suggests a missing link: the ability of the HIF-1 transcription factor to transactivate VHL gene (Figure 1 ). This would establish a feedback loop similar to p53/mdm2. In the case of wt p53, the tumor suppressor is a transcription factor. As a re¯ection in a mirror, the VHL tumor suppressor degrades the HIF-1`oncogenic' transcription factor (Figure 2) . Among HIF-1 inducible genes, Epo (Semenza and Wang, 1992) and Cap43 (Salnikow et al., 2000) possess HIF-1 binding sites in their 3U' untranslated regions. HIF-1 binds the sequence 5'-TACGTGCT-3' in the 3' untranslated region of the Epo enhancer. Like in those genes, the VHL 3' untranslated region (Renbaum et al., 1996) contains consensus HIF-1 binding sites. What could be the reasons that hypoxia-dependence of VHL expression has never been reported? First, VHL may be HIF-1 dependent but not an hypoxia dependent gene. Although seemingly paradoxical, there is no necessity for VHL to be induced under hypoxia, in order to regulate low levels of HIF-1 under normoxia. For the feedback control, VHL must`sense' HIF-1 then destroy HIF-1 in normoxic conditions. During hypoxia, the ability of HIF-1 to transactivate VHL may be counterbalanced by other factors. Again p53 and mdm-2 provide such example. Although mdm-2 is a p53 regulated gene, mdm-2 is downregulated by certain stimuli that induce p53: transcriptional inhibitors, UV light, and antimetobolites Blattner et al., 1999a) . This downregulation of mdm-2 is a driven force for wt p53 accumulation after treatment with transcriptional inhibitors.
Second, many HIF-1 inducible genes are expressed in a tissue speci®c manner. Although Epo is a hypoxiainducible gene, its expression is limited to several cell types.
Third, one can expect that regulation of VHL might be impaired in cancer. Like with other tumor suppressors, the methylation and deacetylation may block the VHL expression (Herman et al., 1994) .
When p53 is mutated, the absence of mdm-2 precludes ubiquitination and proteasomal degradation of p53. The model predicts that, like mutant p53, mutant HIF-1 will be overexpressed. Since VHL (but not HIF-1) is a tumor suppressor, natural mutations occur in VHL but not in HIF-1. However, it has been reported that arti®cial mutant HIF-1 showed lack of ubiquitination and is expressed at high cellular levels (Sutter et al., 2000) .
Are HIF and mdm-2 oncogenes?
Both HIF-1 and Mdm-2 have features of oncogenes (Zhong et al., 1999; Maxwell et al., 1997; Ryan et al., 1998 ), yet it is their tumor suppressor counterparts, VHL and p53, that are more often aected in cancer.
Other activities of VHL and Mdm-2 probably determine nonsymmetry between inactivation of p53 and VHL versus overexpression of Mdm-2 and HIF-1. Thus, the overexpression of Mdm-2 might eliminate not only p53 but also E2F, crucial for proliferation transcription factor, that is also degraded by Mdm-2 (Blattner et al., 1999b) . If VHL is a HIF-1-inducible gene, the overexpression of HIF-1 will induce the VHL tumor suppressor that has other activities such as inhibition of RNA elongation and p27-dependent growth arrest (Duan et al., 1995; Pause et al., 1998) . Therefore, the fact that HIF-1 is not a classical oncogene provides the last albeit circumstantial reason for searching the missing link in a putative HIF-1/VHL feedback loop.
Extending the view
One of the players of p53/mdm-2 and VHL/HIF-1 pairs is a transcription factor (either oncogene or tumor suppressor) and another is a ligase E3-like factor that in turn targets it for degradation (`degradation driver') ( Figure 2 ). The BRCA1 tumor suppressor and transcription factor is also regulated by the protein degradation (Blagosklonny et al., 1999) . The stability of retinoic acid receptor, a transcription factor, is regulated by transcriptional products (Zhu et al., 1999) . It has been shown that gankyrin, an oncoprotein which is a putative cause of hepatocellular carcinoma (one of the most common cancers in Asia and Africa), accelerates the degradation of Rb and was identical to or interacted with a subunit of the 26S proteasome (Higashitsuji et al., 2000) . Before Mdm-2 was implicated in the regulation of p53 degradation, it was known that viral oncoprotein E6, associated with cervical cancers, targets p53 for ubiquitin-dependent degradation. Similarly, viral oncoprotection E7 stimulates the degradation of Rb. Given that viral proteins may imitate cellular oncogenes, a search for cellular analog of E7 is warranted. A loop might involve several steps. For example, while Rb or cyclin D1 are not transcription factors, they modulate the activity of the E2F-1 transcription factor. Both cyclin D1, Rb, and E2F are degraded in a ubiquitin-dependent manner by the proteasome. Like p53, E2F is targeted for degradation by Mdm-2 (Blattner et al., 1999a) . On the other hand, stability of E2F is also regulated by Rb (Campanero and Flemington, 1997) . Why does E2F form multiple functional pairs with both oncogenes and tumor suppressors? First, E2F is both an oncogene and a tumor suppressor (Yamasaki et al., 1996) . It also shares a feedback regulation with p53 (Blattner et al., 1999a) , while p53 may share it with b-catenin (Damalas et al., 1999) (Figure 3a ). An oncoprotein and transcriptional activator, b-catenin, is targeted for degradation by the system that involves APC and some other proteins (see for reference Damalas et al., 1999) . Like for p53, mutations in b-catenin cause its stabilization and accumulation (Figure 3b vs c) . While these mutations are considered to be`activating' (for a decade, mutations in p53 were also considered as activating'), it might have turned out that a mutant bcatenin selectively loses its ability to transactivate gene(s), coding for proteins that otherwise target bcatenin for degradation (Figure 3c ). 
